Despite these positive signals, the clinical evidence remains limited by several key factors: small sample sizes, heterogeneity in probiotic strains, dosages, and administration routes, short follow-up periods, and a primary focus on BV and VVC rather than HPV clearance as the primary endpoint
Two forkhead transcription factors, FOXA2 and O1, have been suggested to function downstream of, and to be negatively regulated by, Akt and are proposed as key determinants of hepatic triglyceride content [118]
Novo has since launched a broad late-stage program for CagriSema, including the Phase III trials REDEFINE 1, which is assessing its efficacy as a weight loss therapy, and REDEFINE 2, designed to include type 2 diabetes patients with excess body weight
The lyophilised peptide vial (the research compound from B.A.B.E LABS) 2